STOCK PURCHASE AND ISSUANCE AGREEMENTStock Purchase and Issuance Agreement • October 1st, 2013 • Oragenics Inc • Pharmaceutical preparations • Florida
THIS STOCK PURCHASE AND ISSUANCE AGREEMENT (“Agreement”) is made and entered into as of September [30], 2013 (the “Effective Date”), by and among Oragenics, Inc., a Florida corporation (the “Company”) and Intrexon Corporation, a Virginia corporation (“Intrexon”).
FIRST AMENDMENT TO THE STOCK PURCHASE AND ISSUANCE AGREEMENTStock Purchase and Issuance Agreement • October 1st, 2013 • Oragenics Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT (the “Amendment”) to the Stock Purchase and Issuance Agreement dated September 30, 2013 (the “Agreement”) by and among Oragenics, Inc., a Florida corporation (the “Company”) and Intrexon Corporation, a Virginia corporation (“Intrexon”), is effective as of September 30, 2013.
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTConfidential Treatment • October 1st, 2013 • Oragenics Inc • Pharmaceutical preparations • New York
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of September 30, 2013 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and ORAGENICS, INC., a Florida corporation having its principal place of business at 4209 Eisenhower Boulevard, Suite 125, Tampa, FL 33634 (“Oragenics”). Intrexon and Oragenics may be referred to herein individually as a “Party”, and collectively as the “Parties.”
